Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Sebastian Palmqvist(Skåne University Hospital), Oskar Hansson(Eli Lilly (United States)), Susanna Calling(Lund University), Rik Ossenkoppele(Malmö University), Erik Stomrud(Lund University), Kaj Blennow(Sahlgrenska University Hospital), Pontus Tideman(Lund University), Tim West(C2N Diagnostics (United States)), Ruben Smith(Lund University), Joel B. Braunstein(C2N Diagnostics (United States)), Niklas Mattsson(Malmö University), Gemma Salvadó(Lund University), Shorena Janelidze(Lund University), Philip B. Verghese(C2N Diagnostics (United States)), Suzanne E. Schindler(Washington University in St. Louis), Mark Monane(C2N Diagnostics (United States))
Cited by 317
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.3k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k